In addition to tivantinib exhibiting potent single agent activity in AML, we observed that the BCL-2 inhibitor ABT-199, which displays activity and is in clinical trials in AML39, synergizes with tivantinib by further enhancing tivantinib’s already potent ability to inhibit cell viability and induce apoptosis. The gene discussed is BCL2; the disease is acute myeloid leukemia.